Levy, Mark L http://orcid.org/0000-0002-1807-3246
Garnett, Fiona
Kuku, Adedayo
Pertsovskaya, Inna
McKnight, Eddie
Haughney, John
Funding for this research was provided by:
IMPACT service is conducted by NSHI Ltd and funded with institutional support from Teva UK Limited
Article History
Received: 21 December 2017
Revised: 6 June 2018
Accepted: 7 June 2018
First Online: 26 July 2018
Competing interests
: M.L.L. has received reimbursements for attending symposia, fees for speaking, fees for consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, TEVA, NAPP Pharmaceuticals, SOAR Beyond, Clement Clarke International and NSHI. J.H. has received reimbursements for attending symposia, fees for speaking, organizing educational events, funds for research or fees for consulting from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Mundipharma, Novartis, Pfizer, Teva and Zentiva. I.P. is an employee of NSHI Ltd. E.Mc.K. is the Managing Director of NSHI Ltd. The remaining authors declare no competing interests..